| Title |
New and emerging treatments for symptomatic tardive dyskinesia
|
|---|---|
| Published in |
Drug Design, Development and Therapy, November 2013
|
| DOI | 10.2147/dddt.s32328 |
| Pubmed ID | |
| Authors |
Abdul Qayyum Rana, Zishan M Chaudry, Pierre J Blanchet |
| Abstract |
The aim of this review is to assess new, emerging, and experimental treatment options for tardive dyskinesia (TD). The methods to obtain relevant studies for review included a MEDLINE search and a review of studies in English, along with checking reference lists of articles. The leading explanatory models of TD development include dopamine receptor supersensitivity, GABA depletion, cholinergic deficiency, neurotoxicity, oxidative stress, changes in synaptic plasticity, and defective neuroadaptive signaling. As such, a wide range of treatment options are available. To provide a complete summary of choices we review atypical antipsychotics along with resveratrol, botulinum toxin, Ginkgo biloba, tetrabenazine, clonazepam, melatonin, essential fatty acids, zonisamide, levetiracetam, branched-chain amino acids, drug combinations, and invasive surgical treatments. There is currently no US Food and Drug Administration-approved treatment for TD; however, prudent use of atypical antipsychotics with routine monitoring remain the cornerstone of therapy, with experimental treatment options available for further management. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 40% |
| United States | 1 | 20% |
| United Kingdom | 1 | 20% |
| Unknown | 1 | 20% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
| Unknown | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 128 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 126 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 14% |
| Student > Bachelor | 15 | 12% |
| Student > Ph. D. Student | 14 | 11% |
| Student > Master | 14 | 11% |
| Student > Postgraduate | 11 | 9% |
| Other | 32 | 25% |
| Unknown | 24 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 50 | 39% |
| Agricultural and Biological Sciences | 9 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Psychology | 7 | 5% |
| Nursing and Health Professions | 6 | 5% |
| Other | 18 | 14% |
| Unknown | 30 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2022.
All research outputs
#6,361,124
of 25,654,806 outputs
Outputs from Drug Design, Development and Therapy
#412
of 2,276 outputs
Outputs of similar age
#53,505
of 227,332 outputs
Outputs of similar age from Drug Design, Development and Therapy
#6
of 40 outputs
Altmetric has tracked 25,654,806 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,276 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 227,332 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.